Texas Veteran With PTSD Explains Why She Made Public a Voicemail She Received From Beto O'Rourke, and Now We're Crying
At the end of August, President Donald Trump took to Twitter to give his one-time rival, Republican Senator Ted Cruz of Texas, his standard endorsement message. However, unlike most of his other tweets that include the same phrase touting GOP strength, the President substituted an attack on Cruz's opponent.
In his message, Trump took a shot at El Paso, Texas, native, Democratic Representative Beto O'Rourke. The President called out O'Rourke as "a disaster for Texas - weak on Second Amendment, Crime, Borders, Military, and Vets!"
It is known by many names in popular culture: “hug drug,” “love drug,” “dance drug,” “ecstasy,” “XTC” and “Molly” — along with its scientific designation: MDMA. Now, the Food and Drug Administration (FDA) has bestowed an additional moniker: “breakthrough therapy.”
The FDA has announced that it is considering MDMA as a therapy to treat veterans with PTSD.
The Need to Travel With Emotional Support Animals Is Real, but Some Are Ruining It for the Rest of Us
As more people globally are living with mental illnesses such as Post Traumatic Stress Disorder (PTSD) and depression, the safety and comfort of support animals is growing in popularity. Traveling with Emotional Support Animals (ESAs), however, can be a challenge, largely because not every mode of transportation allows for animals.
Recently a student traveling home on Spirit Airlines attempted to bring her companion dwarf hamster along with her. The Transportation Safety Administration allows for traveling with just about any licensed emotional support pets; Spirit Airlines, however, does not.
Drug Scheduling and Breakthrough Therapy
MDMA (3,4 methylenedioxymethamphetamine), the molecule comprising the popular party drug dubbed “Ecstasy,” was cleared by the Food and Drug Administration in August 2017 as a breakthrough therapy for the treatment of Post-Traumatic Stress Disorder.
Breakthrough Therapy Designation was introduced in 2012 as part of the Food and Drug Administration Safety and Innovation Act. “Breakthrough therapy designation is intended to expedite the development and review of drugs for serious or life-threatening conditions,” according to the FDA. Thus, obtaining breakthrough therapy status means MDMA can be used in FDA-approved clinical trials for treating PTSD, the goal of which is the approval of MDMA for pharmaceutical use. A press release by the Multidisciplinary Association for Psychedelic Studies (MAPS), the organization that ran the clinical trials, states, “MDMA-assisted psychotherapy is a novel treatment package that combines psychotherapeutic techniques with three administrations of MDMA as a pharmacological adjunct.”